Catalent Signs RL21 Anti-Cancer Development Deal with Pure MHC
Catalent has signed a product development agreement with immunology company Pure MHC (major histocompatibility complex), which specializes in MHC-based diagnostics and therapeutics.
Catalent announced that it has signed a product development agreement with immunology company Pure MHC (major histocompatibility complex), which specializes in MHC-based diagnostics and therapeutics.
Under the terms of the agreement, Catalent will develop a humanized version of Pure MHC’s proprietary RL21A antibody and engineer a cell line to express the antibody using Catalent’s GPEx technology. Catalent will subsequently produce purified monoclonal antibodies to support Pure MHC’s preclinical development in preparation for clinical trials with humanized RL21A for the treatment of cancer. GPEx technology is used to generate mammalian cells with high yields and stability, helping to speed drugs to clinic.
Pure MHC has developed a suite of MHC/ligand targets that recognize cancerous cells in addition to producing monoclonal antibodies for these distinct MHC/ligand cancer targets. Antibodies such as RL21A distinguish primary cancers from healthy tissue and, in animal models, have been shown to arrest tumor development.
Source: Catalent
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Telix Enters Agreement with ImaginAb to Purchase Next-Gen Therapeutic Candidates
Published: January 13th 2025 | Updated: January 13th 2025The transaction adds a pipeline of early-stage drug candidates against high-value targets to Telix’s portfolio, along with other novel targets currently in the discovery stage.
